Welcome to our dedicated page for Iqvia Hldgs news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on Iqvia Hldgs stock.
IQVIA Holdings Inc. reports developments tied to its role as a global provider of clinical research services, commercial insights and healthcare intelligence for life sciences and healthcare customers. Company news commonly covers quarterly results for R&D Solutions and Commercial Solutions, contracted clinical-development activity, earnings guidance and management presentations at healthcare conferences.
Updates also include capital actions such as common-stock repurchase authorizations and technology announcements involving IQVIA Connected Intelligence™, Healthcare-grade AI® and IQVIA.ai, a unified agentic AI platform for clinical, commercial and real-world domains.
IQVIA Holdings Inc. reported strong first-quarter 2022 results with revenue reaching $3,568 million, a 4.7% year-over-year increase. GAAP net income surged 53.3% to $325 million, while GAAP diluted EPS rose 54.1% to $1.68. Adjusted EBITDA was $812 million, up 9.1%. The record R&D solutions bookings exceeded $1.9 billion, with a backlog over $25 billion. Full-year revenue guidance has been updated to $14,450 million to $14,750 million, reflecting a 4.2% to 6.3% reported growth. Despite macro challenges, adjustments to EBITDA and EPS guidance reaffirm expected growth.
In 2021, spending on medicines in the U.S. reached $407 billion, a 12% increase from 2020, driven largely by COVID-19 vaccines and therapeutics. Prescription drug use hit a record 194 billion daily doses, with overall drug spending expected to return to pre-pandemic growth by 2023. However, patient out-of-pocket costs rose $4 billion in 2021, reflecting ongoing economic pressures. The report indicates a shift towards biosimilars affecting branded drug sales and forecasts a 2.1% compound annual growth in medicine spending through 2026.
IQVIA Holdings Inc. will announce its first-quarter 2022 financial results on April 27, 2022, before the market opens. The management will host a conference call and webcast at 9:00 a.m. Eastern Time. Interested participants must register in advance to join the call and will receive details via email. A replay of the webcast will be accessible two hours post-event. IQVIA is a leading provider of analytics and clinical research services in the life sciences, operating in over 100 countries with about 79,000 employees.
IQVIA (NYSE:IQV) has secured a contract from the European Medicines Agency (EMA) to provide analytics services for the DARWIN EU® Coordination Centre, managed by Erasmus University Medical Center Rotterdam. This initiative aims to establish a pan-European network of real-world healthcare data systems, enhancing the regulatory decision-making process for drug safety and effectiveness. Over two years, IQVIA will contribute technical expertise and management for pharmacovigilance data, improving data standardization and accessibility for regulatory agencies.
IQVIA (NYSE:IQV) has launched OCE+, an upgrade to its customer engagement platform. This innovation introduces the Next Best recommendation engine, providing AI-driven suggestions to healthcare professionals (HCP) for optimized engagement. OCE+ aims to enhance productivity, the HCP experience, and return on investment (ROI). By integrating sophisticated data analytics and AI, it facilitates informed decision-making for life sciences teams, promoting better personalization and increased efficiency in customer interactions.
IQVIA Holdings Inc. (NYSE:IQV) announced the appointment of Costa Panagos as president of its Research & Development Solutions unit, succeeding Richard Staub III, who is retiring after over three decades. Panagos, with 25 years of industry experience, was previously the president of R&D Operations and CEO of Q2 Solutions. His effective date is April 1, 2022. Richard Staub will remain with the company as a senior advisor, aiding in business development and client management. This transition is expected to be quick and seamless, as per CEO Ari Bousbib.
IQVIA Holdings Inc. (NYSE:IQV) announced that Ron Bruehlman, CFO, will speak at the Barclays Global Healthcare Conference in Miami, FL on March 16, 2022, at 1:35 p.m. ET. A live audio webcast of the presentation will be accessible via the IQVIA Investor Relations website, with a replay available later that day. IQVIA is a global leader in advanced analytics and clinical research services for the life sciences sector, operating in over 100 countries with approximately 79,000 employees and focusing on improving healthcare outcomes through innovative solutions.
IQVIA has entered into a multi-year collaboration with argenx SE to develop new indications for VYVGART™ (efgartigimod alfa fcab), an FDA-approved treatment for generalized myasthenia gravis. The undisclosed terms of the agreement will enhance clinical development, regulatory, and commercial strategies. IQVIA aims to support argenx in accelerating this process, leveraging its expertise in analytics and technology. With approximately 79,000 employees operating in over 100 countries, IQVIA continues to emphasize its role in improving healthcare outcomes.
Summary not available.
Summary not available.